Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL5126916 | 0.93 | SMN1; SMN2 (0.44) | SMN1; SMN2HTTLMNAMEN1KMT2A | |
| Formamide SCHEMBL5115801 | 0.88 | CXCR3 (0.47) | CXCR3 | |
| Formamide SCHEMBL5117411 | 0.87 | HTT (0.44) | SMN1; SMN2HTTCNR1CNR2NPSR1 | |
| SCHEMBL1456982 | 0.82 | HRH3 (0.48) | SMN1; SMN2HTTLMNAMEN1RECQL | |
| SCHEMBL1457103 | 0.80 | NPC1 (0.45) | SMN1; SMN2LMNAMEN1RECQLKMT2A | |
| Formamide SCHEMBL5119758 | 0.79 | KCNH2 (0.41) | MEN1KMT2ACXCR3CYP2C19 | |
| Formamide SCHEMBL5112955 | 0.75 | GFER (0.47) | SMN1; SMN2LMNAMAPT | |
| Formamide SCHEMBL5116397 | 0.75 | DRD2 (0.38) | SMN1; SMN2CNR2MAPT | |
| SCHEMBL1457198 | 0.75 | NAMPT (0.48) | LMNAMAPT | |
| SCHEMBL1457242 | 0.75 | HRH3 (0.45) | SMN1; SMN2HTTLMNAMEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | claimed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | SMN1; SMN2 4677/4885HTT 1428/4885LMNA 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.